Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	236.30B
Revenue (ttm)	2.52B
Net Income (ttm)	-13.28B
Shares Out	6.55M
EPS (ttm)	-2,430.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,491
Average Volume	171,311
Open	35,850
Previous Close	35,800
Day's Range	35,550 - 37,000
52-Week Range	23,000 - 52,000
Beta	n/a
RSI	55.16
Earnings Date	Nov 14, 2025

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 76
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2024, Organoidsciences's revenue was 1.95 billion, an increase of 22.77% compared to the previous year's 1.59 billion. Losses were -11.25 billion, -70.93% less than in 2023.